Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Arena Pharmaceuticals (ARNA)

Arena Pharmaceuticals (ARNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,318,215
  • Shares Outstanding, K 50,337
  • Annual Sales, $ 806,430 K
  • Annual Income, $ 397,560 K
  • 60-Month Beta 1.45
  • Price/Sales 4.10
  • Price/Cash Flow 8.34
  • Price/Book 3.35

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -2.08
  • Number of Estimates 4
  • High Estimate -1.81
  • Low Estimate -2.21
  • Prior Year -1.24
  • Growth Rate Est. (year over year) -67.74%

Price Performance

See More
Period Period Low Period High Performance
1-Month
59.83 +10.18%
on 06/12/20
67.50 -2.34%
on 06/23/20
+1.32 (+2.04%)
since 06/10/20
3-Month
44.79 +47.18%
on 05/14/20
69.75 -5.49%
on 06/03/20
+18.62 (+39.37%)
since 04/09/20
52-Week
32.95 +100.06%
on 03/18/20
69.75 -5.49%
on 06/03/20
+5.06 (+8.31%)
since 07/10/19

Most Recent Stories

More News
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

, /PRNewswire/ -- (Nasdaq: ARNA) today announced that on , the Compensation Committee of its Board of Directors granted inducement stock options to purchase an aggregate of 80,250 shares of its common...

ARNA : 65.92 (+0.26%)
Arena Pharmaceuticals Appoints Biotech Executive Katharine Knobil, M.D., to Board of Directors

, /PRNewswire/ -- (Nasdaq: ARNA) today announced the appointment of Dr. to the Company's Board of Directors. Dr. Knobil brings more than 20 years of leadership and expertise across a range of areas...

ARNA : 65.92 (+0.26%)
Metacrine Appoints Pharmaceutical Business and R&D Executive, Preston Klassen, M.D., MHS, as President and Chief Executive Officer

Metacrine, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing best-in-class drugs to treat patients with liver and gastrointestinal diseases, today announced the appointment...

ARNA : 65.92 (+0.26%)
ASMB : 23.02 (-2.58%)
Arena Pharmaceuticals Announces R&D Leadership Transition

, /PRNewswire/ -- (Nasdaq: ARNA) today announced changes to its research and development leadership team. Effective , Dr. will be leaving the Company to pursue an opportunity as Chief Executive Officer...

ARNA : 65.92 (+0.26%)
Arena Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares

, /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the completion of its previously announced underwritten public offering of 6,325,000 shares of its common stock at a price...

ARNA : 65.92 (+0.26%)
Moving Average Crossover Alert: Arena Pharmaceuticals

Arena Pharmaceuticals, Inc. (ARNA) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

ARNA : 65.92 (+0.26%)
Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock

, /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a price to the public of per share....

ARNA : 65.92 (+0.26%)
Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock

, /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, of its...

ARNA : 65.92 (+0.26%)
Arena Completes Full Enrollment of Etrasimod Phase 2 ADVISE Trial for Atopic Dermatitis, Provides Program Updates

, /PRNewswire/ --  (Nasdaq: ARNA) today announced that it has completed full enrollment of the Phase ADVISE trial evaluating etrasimod, an investigational next-generation, once-daily, oral, highly selective...

ARNA : 65.92 (+0.26%)
Arena Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders

, /PRNewswire/ --  (Nasdaq: ARNA) today announced that, due to public health and safety concerns related to the COVID-19 global pandemic, recommendations and orders from federal, state and local authorities,...

ARNA : 65.92 (+0.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade ARNA with:

Business Summary

Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs. BELVIQ (lorcaserin HCl), their internally discovered drug for chronic weight management, is their...

See More

Key Turning Points

2nd Resistance Point 67.76
1st Resistance Point 66.84
Last Price 65.92
1st Support Level 64.91
2nd Support Level 63.90

See More

52-Week High 69.75
Last Price 65.92
Fibonacci 61.8% 55.69
Fibonacci 50% 51.35
Fibonacci 38.2% 47.01
52-Week Low 32.95

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar